^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

seliciclib (CYC202)

i
Other names: CYC202, CY-202, CYC 202
Associations
Company:
Cedars-Sinai, Cyclacel
Drug class:
CDK9 inhibitor, MCL1 inhibitor, CDK7 inhibitor, CDK2 inhibitor
Related drugs:
Associations
17d
Molecular docking, DFT and antiproliferative properties of 4-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency. (PubMed, Drug Dev Res)
Compound 3 exhibited an IC50 of 0.30 µM for CDK2 inhibition, making it five times less active than Roscovitine, which has an IC50 of 0.06 µM. However, compound 3 demonstrated slightly better inhibition of PIM1 compared to Staurosporine. These findings suggest that compound 3 is a promising anticancer agent with the potential for further development into a highly active compound.
Journal
|
PIM1 (Pim-1 Proto-Oncogene)
|
seliciclib (CYC202)
29d
Development and Validation of a Comprehensive Prognostic and Depression Risk Index for Gastric Adenocarcinoma. (PubMed, Int J Mol Sci)
With the Genomics of Drug Sensitivity in Cancer database, we found that the gastric adenocarcinoma patients with high risk-score may be sensitive to Pazopanib, XMD8.85, Midostaurin, HG.6.64.1, Elesclomol, Linifanib, AP.24534, Roscovitine, Cytarabine, and Axitinib. The gene signature consisting of the NDUFA4L2, ANKRD45, and AQP3 genes is a promising biomarker to distinguish the prognosis, the molecular and immune characteristics, the depressive risk, and the therapy candidates for gastric adenocarcinoma patients.
Journal
|
NDUFA4L2 (NDUFA4 Mitochondrial Complex Associated Like 2)
|
cytarabine • Iclusig (ponatinib) • pazopanib • Rydapt (midostaurin) • Inlyta (axitinib) • elesclomol (STA-4783) • linifanib (ABT-869) • seliciclib (CYC202)
1m
Design, synthesis and in vitro anti-proliferative evaluation of new pyridine-2,3-dihydrothiazole/thiazolidin-4-one hybrids as dual CDK2/GSK3β kinase inhibitors. (PubMed, RSC Adv)
The three promising anti-proliferative hybrids (1a, 8a, 13a) were selected for the assessment of their in vitro inhibitory kinase activity against CDK2/GSK3β using roscovitine (IC50 = 0.88 μg mL-1) and CHIR-99021 (IC50 = 0.07 μg mL-1) as references, respectively...Moreover, it resulted in an increase in Bax and caspase-3 with a decrease in Bcl-2 levels in HepG2 cells compared with untreated cells. Finally, in silico drug likeness/ADME prediction for the three potent compounds as well as a molecular docking simulation study were conducted in order to explore the binding affinity and interactions in the binding site of each enzyme, which inspired their usage as anti-proliferative leads for further modification.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
seliciclib (CYC202)
1m
Reciprocal regulation of oxidative stress and mitochondrial fission augments parvalbumin downregulation through CDK5-DRP1- and GPx1-NF-κB signaling pathways. (PubMed, Cell Death Dis)
N-acetylcysteine (NAC), roscovitine and Mdivi-1 ameliorated SE-induced PV neuronal degeneration by mitigating CDK5 Y15 hyperphosphorylation, aberrant mitochondrial fragmentation and reduced GPx1-mediated NF-κB inhibition. Furthermore, SN50 (a NF-κB inhibitor) alleviated SE-induced PV neuronal degeneration, independent of dysregulation of mitochondrial fission, CDK5 hyperactivation and GPx1 downregulation. These findings provide an evidence that oxidative stress may activate CDK5-DRP1- and GPx1-NF-κB-mediated signaling pathways, which would be possible therapeutic targets for preservation of PV neurons in various diseases.
Journal
|
CDK5 (Cyclin Dependent Kinase 5)
|
seliciclib (CYC202)
2ms
Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation. (PubMed, Bioorg Chem)
Additionally, 5g and 5i demonstrated 7.80-fold and 1.54-fold greater cytotoxicity against PA-1 and MCF-7, with IC50s of 1.08 µM and 3.54 µM, respectively, compared to seliciclib (8.43 µM and 5.46 µM)...Moreover, it triggered cell death by apoptosis and cell cycle arrest in G2/M. Taken together, 5g merits further investigation in PKPD research to discover a potential therapeutic candidate against cancer.
Journal
|
CCNA2 (Cyclin A2)
|
seliciclib (CYC202)
2ms
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. (PubMed, Nat Cell Biol)
Treatment with roscovitine-a clinically applicable Cdk5 inhibitor-alone or combined with immune checkpoint inhibitors, significantly reduces BrM burden and increases tumour-infiltrating functional CD8+ lymphocytes in mice. Thus, astrocyte-induced Cdk5 overexpression endorses BrM immune evasion, whereas therapeutically targeting Cdk5 markedly improves the efficacy of immune checkpoint inhibitors and inhibits BrM growth.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • NLRC5 (NLR Family CARD Domain Containing 5) • CDK5 (Cyclin Dependent Kinase 5)
|
seliciclib (CYC202)
4ms
Comprehensive analysis of CPNE1 predicts prognosis and drug resistance in gastric adenocarcinoma. (PubMed, Am J Transl Res)
CPNE1 could be a predictive biomarker and a potential target for biological therapy in STAD.
Journal • PARP Biomarker
|
CPNE1 (Copine 1)
|
Lynparza (olaparib) • Koselugo (selumetinib) • Iclusig (ponatinib) • pazopanib • Rubraca (rucaparib) • Torisel (temsirolimus) • Inlyta (axitinib) • refametinib (BAY86-9766) • AZD8055 • seliciclib (CYC202)
5ms
Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients' prognosis. (PubMed, PeerJ)
Patients in low ASR group responded more actively to traditional chemotherapy drugs (Erlotinib and Roscovitine). CellChat analysis revealed that high ARS cell groups communicated with immune cells via SPP1 (ITGA4-ITGB1) and MK (MDK-NCl) signaling pathways. In this research, integrative analysis based on the ARS model provided a potential direction for improving the diagnosis and treatment of LUAD.
Journal • Gene Signature • IO biomarker
|
SPP1 (Secreted Phosphoprotein 1) • ITGA4 (Integrin, alpha 4) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1) • BCLAF1 (BCL2 Associated Transcription Factor 1) • ITGB1 (Integrin Subunit Beta 1) • UQCRB (Ubiquinol-Cytochrome C Reductase Binding Protein)
|
erlotinib • seliciclib (CYC202)
5ms
Cytoprotective Role of Autophagy in CDIP1 Expression-Induced Apoptosis in MCF-7 Breast Cancer Cells. (PubMed, Int J Mol Sci)
In this study, we first demonstrated that CDIP1 was upregulated after treatment with the anticancer drug adriamycin in human breast cancer MCF-7 cells but was degraded rapidly in the lysosomal pathway. We also demonstrated that treatment with the cyclin-dependent kinase 5 (CDK5) inhibitor roscovitine led to an increase in the electrophoretic mobility of CDIP1...Treatment of cells expressing CDIP1 with SAR405, an inhibitor of the class III phosphatidylinositol 3-kinase VPS34, caused a reduction in autophagy and promoted apoptosis. Therefore, autophagy is thought to be a defense mechanism against CDIP1 expression-induced apoptosis.
Journal
|
BAP1 (BRCA1 Associated Protein 1)
|
doxorubicin hydrochloride • seliciclib (CYC202)
6ms
Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression: Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR. (PubMed, Purinergic Signal)
In addition, e-ATP-induced Caco-2 cell proliferation as well as cell survival were highly reduced in the presence of either PPADS or DHTS or selective CDK-2 inhibitor (Roscovitine) or selective Bcl-2 inhibitor (ABT-263). Furthermore, it was found that MMP-9 is critical for Caco-2 cells migration induced by e-ATP as demonstrated by a clear reduction in cells migration in the presence of a selective MMP-9 inhibitor (Marimastat). Collectively, these data demonstrate that ATP through P2R activation can induce HuR nucleocytoplasmic shuttling that could be translated into an increase in cancer-related genes expression and subsequent, cell proliferation and progression.
Journal • IO biomarker
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CCNA2 (Cyclin A2) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
navitoclax (ABT 263) • seliciclib (CYC202)
6ms
Cymbopogon proximus phytochemicals induce S-phase arrest in A549 lung cancer cell lines via CDK2/cyclin A2 inhibition: gas chromatography-mass spectrometry and molecular docking analyses. (PubMed, Z Naturforsch C J Biosci)
In-vitro cytotoxic activity of C. proximus extracts was examined against liver (HepG2), lung (A549), prostate (PC3), and bone (MG63) cell lines using MTT assay in comparison to doxorubicin. Di-N-octyl phthalate, 3-β-hydroxylean-11.13(18)-dien-30-oic acid methyl ester, elemol hydrocarbons, linoelaidic acid and linoleic acid demonstrated the lowest docking binding scores and similar binding modes against CDK2 as compared to that attained by the native ligand R-Roscovitine "CDK2 ATP inhibitor". Western blot analysis demonstrated that CDK2/cyclinA2 protein expression has been suppressed in A549 cell lines by Pet.Eth fraction.
Preclinical • Journal
|
CCNA2 (Cyclin A2)
|
doxorubicin hydrochloride • seliciclib (CYC202)
6ms
An E7-retinoblastoma protein pathway mechanism may account for the higher carcinogenic ability of HPV16 over HPV58 in cervical cancer. (PubMed, Transl Cancer Res)
Roscovitine restored Rb expression and decreased the cell activity in zebrafish. HPV16 possesses a stronger carcinogenic ability than does HPV 58, and the mechanism underlying this effect may be the impairment of the E7-Rb pathway.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
seliciclib (CYC202)
8ms
Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells. (PubMed, Front Chem)
Remarkably, they demonstrated potent EGFR inhibition, with IC50 values of 0.026, 0.067, and 0.04 μM and inhibition percentages of 92.6%, 89.8%, and 91.2%, respectively, when compared to Erlotinib (IC50 = 0.03 μM, 95.4%). Furthermore, these compounds exhibited potent CDK-2 inhibition, with IC50 values of 0.301, 0.345, and 0.557 μM and inhibition percentages of 91.9%, 89.4%, and 88.7%, respectively, in contrast to Roscovitine (IC50 = 0.556 μM, 92.1%)...Treatment with 5g increased the gene expression of pro-apoptotic genes P53, Bax, caspases 3, 8, and 9 with notable fold changes while decreasing the expression of the anti-apoptotic gene Bcl-2. Molecular docking and dynamic simulations (100 ns simulation using AMBER22) were conducted to investigate the binding mode of the most potent candidates, namely, 5g, 5l, and 5n, within the active sites of EGFR and CDK-2.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BCL2 expression • TP53 expression • BAX expression
|
erlotinib • seliciclib (CYC202)
9ms
Novel tetrahydroisoquinolines as DHFR and CDK2 inhibitors: synthesis, characterization, anticancer activity and antioxidant properties. (PubMed, BMC Chem)
Compound 7e exhibited the most potent cytotoxic activity against A549 cell line (IC50: 0.155 µM) while compound 8d showed the most potent one against MCF7 cell line (IC50: 0.170 µM) in comparison with doxorubicin...Our findings by docking and experimental studies that compound 7e is a potent CDK2 inhibitor with IC50 of 0.149 µM, compared to the Roscovitine control drug with IC50 of 0.380 µM. We also found that compound 8d is a significant DHFR inhibitor with an IC50 of 0.199 µM, compared to Methotrexate control drug with IC50 of 0.131 µM. Evaluation of the antioxidant properties of ten compounds was also studied in comparison with Vitamin C. Compounds 1, 3, 6, 7c and 8e have higher antioxidant activity than Vitamin C which mean that these compounds can used as potent antioxidant drugs.
Journal
|
ANXA5 (Annexin A5)
|
doxorubicin hydrochloride • methotrexate • seliciclib (CYC202)
9ms
p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer. (PubMed, Anticancer Res)
CDK5 might play important roles in bladder cancer progression and be a potential diagnostic and therapeutic target in the near future.
Journal
|
CDK5 (Cyclin Dependent Kinase 5)
|
seliciclib (CYC202)
12ms
Prognostic value analysis of cholesterol and cholesterol homeostasis related genes in breast cancer by Mendelian randomization and multi-omics machine learning. (PubMed, Front Oncol)
It can also optimize the administration of various first-line drugs, including AKT inhibitors VIII Imatinib, Crizotinib, Saracatinib, Erlotinib, Dasatinib, Rapamycin, Roscovitine and Shikonin in BC patients. Finally, we employed machine learning techniques to construct a multi-omics prediction model(Risklight),with an area under the feature curve (AUC) of up to 0.89. With the help of CAG_score and Risklight, we reveal the signature of cholesterol homeostasis-related genes for angiogenesis, immune responses, and the therapeutic response in breast cancer, which contributes to precision medicine and improved prognosis of BC.
Journal • Machine learning
|
CDH5 (Cadherin 5) • CLDN5 (Claudin 5)
|
Xalkori (crizotinib) • erlotinib • dasatinib • imatinib • sirolimus • saracatinib (AZD0530) • seliciclib (CYC202)
1year
Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer. (PubMed, Front Oncol)
Additionally, by applying our prediction model, we segregated PC patients into high-risk and low-risk groups, identifying potential benefits of cisplatin, docetaxel, pazopanib, midostaurin, epothilone.B, thapsigargin, bryostatin.1, and AICAR for high-risk PC patients, and metformin, roscovitine, salubrinal, and cyclopamine for those in the low-risk group. This study unveils IFN-γGs related molecular subsets in pancreatic cancer for the first time, shedding light on the pivotal role of IFN-γGs in the progression of PC. Furthermore, we establish an IFN-γGs related prognostic model for predicting the survival of PC, offering a theoretical foundation for exploring the precise mechanisms of IFN-γGs in PC.
Journal
|
IFNG (Interferon, gamma)
|
IFNG expression
|
cisplatin • docetaxel • pazopanib • Rydapt (midostaurin) • metformin • cyclopamine • salubrinal • patupilone (EPO 906) • seliciclib (CYC202)
1year
Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases. (PubMed, Rev Med Virol)
So far, several drugs or biomolecules have been discovered that can target EBV-encoded products for treatment, such as Silvestrol, affinity toxin, roscovitine, H20, H31, curcumin, thymoquinone, and ribosomal protein L22...Additionally, some promising findings in the fields of vaccines, immunological, and cellular therapies have been established. In this review, we mainly summarise the function of drugs mentioned above and unique mechanisms, hoping that we can help giving insight to the design of drugs for the treatment of EBV-associated diseases.
Review • Journal
|
RPL22 (Ribosomal Protein L22)
|
seliciclib (CYC202)
1year
Inhibition of GCN2 Reveals Synergy with Cell-Cycle Regulation and Proteostasis. (PubMed, Metabolites)
Inhibitors of proteostasis and the MEK-ERK pathway, as well as the pan-CDK inhibitors, flavopiridol, and seliciclib, were potently synergistic with TAP20 in two cell lines. However, TAP20 alone was sufficient to restrict invasion at concentrations well below its growth-inhibitory IC. We conclude that GCN2 inhibition can be further explored in vivo as a cancer target.
Journal
|
CDK7 (Cyclin Dependent Kinase 7)
|
alvocidib (DSP-2033) • seliciclib (CYC202)
1year
Synthesis and Anti-Breast Cancer Potency of Mono- and Bis-(pyrazolyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors. (PubMed, ACS Omega)
Compounds 4b, 4c, and 6a also showed promising dual EGFR and CDK-2 inhibition activities, particularly 6a was the most effective (IC = 19.6 and 87.9 nM, respectively), better than Erlotinib and Roscovitine. Compound 6a treatment induced EGFR and CDK-2 enzyme inhibition by 97.18% and 94.11%, respectively, at 10 μM (the highest concentration). Compound 6a notably induced cell apoptosis in MCF-7 cells, increasing the cell population by total apoptosis 43.3% compared to 1.29% for the untreated control group, increasing the cell population at the S-phase by 39.2% compared to 18.6% (control).
Journal
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • seliciclib (CYC202)
1year
Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer. (PubMed, Bioorg Chem)
Moreover, FD2056 showed more efficacious anti-TNBC activity than the corresponding drugs BKM120 and CYC202 at an oral dose of 15 mg/kg in the MDA-MB-231 xenograft model, inhibiting tumor growth by 43% with no observable toxic effects. All these results suggest that FD2056 has potential for further development as a promising anticancr compound, and co-targeting PI3K and CDK2 pathways may provide an alternative therapeutic strategy for the treatment of TNBC.
Journal
|
buparlisib (AN2025) • seliciclib (CYC202)
1year
A New Saponin (Zygo-albuside D) from Zygophyllum album Roots Triggers Apoptosis in Non-Small Cell Lung Carcinoma (A549 Cells) through CDK-2 Inhibition. (PubMed, ACS Omega)
The new saponin (1) exhibited promising cytotoxicity with IC values of 3.5 and 5.52 μM on A549 and PC-3 cancer cell lines, respectively, compared to doxorubicin with IC values of 9.44 and 11.39 μM on A549 and PC-3 cancer cell lines, respectively...Compound 1 exhibited remarkable CDK-2 target inhibition by 96.2% with an IC value of 117.6 nM compared to Roscovitine. The molecular docking study further confirmed the binding affinity of compound 1 as CDK2 and Bcl2 inhibitors that led to apoptosis induction in A549 cancer cells. Hence, this study highlights the importance of compound 1 in the design of a new anticancer agent with specific mechanisms.
Journal • IO biomarker
|
doxorubicin hydrochloride • seliciclib (CYC202)
over1year
Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities. (PubMed, Arch Pharm (Weinheim))
The candidate 8c exhibited more potent activity (10.10- and 2.27-fold) than the standard drug roscovitine (IC  = 1.91 ± 0.17 µM (MCF-7) and 2.36 ± 0.21 µM (HepG2)). Compound 8c was investigated for epidermal growth factor receptor (EGFR) inhibition; it exhibited promising IC values of 96.6 nM compared with 67.3 nM for erlotinib...Additionally, for apoptosis induction of compound 8c in MCF-7, it upregulated the expression levels of proapoptotic genes for P53, Bax, caspases-3, 8, and 9 at up to 6.18, 4.8, 9.8, 4.6, 11.3 fold-change, respectively, and downregualted the level of the antiapoptotic gene for Bcl-2 by 0.14-fold. Finally, a molecular docking study of the most active compound 8c highlighted a good binding affinity with Lys89 as the key amino acid for CDK-2 inhibition.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
|
erlotinib • seliciclib (CYC202)
over1year
Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma. (PubMed, Front Pharmacol)
Small-molecule drugs panobinostat, oxaliplatin, ixabepilone, and seliciclib were significantly associated with ADH1B. Our study provides ADH1B as a key afatinib-related gene, which is associated with the immune microenvironment and can be used to predict the prognosis of LIHC. It is also a potential target of candidate drugs, sharing a promising approach to the development of novel drugs for the treatment of LIHC.
Journal
|
EGFR (Epidermal growth factor receptor) • CDK4 (Cyclin-dependent kinase 4) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • ANXA10 (Annexin A10) • ASPM (Assembly Factor For Spindle Microtubules) • PON1 (Paraoxonase 1)
|
Gilotrif (afatinib) • oxaliplatin • Farydak (panobinostat) • Ixempra (ixabepilone) • seliciclib (CYC202)
over1year
Advances in lung adenocarcinoma: A novel perspective on prognoses and immune responses of CENPO as an oncogenic superenhancer. (PubMed, Transl Oncol)
CENPO was found to be positively associated with the expression levels of immune checkpoints and drug IC50 value (Roscovitine and TGX221), but negatively associated with the fraction levels of several immature cells and drug IC50 value (CCT018159, GSK1904529A, Lenaildomide, and PD-173074). The removal of CENPO significantly suppressed metastasis and induced arrest and apoptosis of LUAD cells. The involvement of CENPO in the immunosuppression of LUAD provides a prognostic signature for LUAD patients.
Journal
|
TGX-221 • seliciclib (CYC202)
over1year
Design, synthesis, and biological evaluation of furan-bearing pyrazolo[3,4-b]pyridines as novel inhibitors of CDK2 and P53-MDM2 protein-protein interaction. (PubMed, Drug Dev Res)
Compounds 7b and 12f displayed enhanced activity (half-maximal inhibitory concentration [IC ] = 0.46 and 0.27 µM, respectively) in comparison to the standard roscovitine (IC  = 1.41 ± 0.03 µM), in addition to, cell cycle arrest at S phase and G1/S transition phase in MCF7 cells treated with both compounds, respectively...Molecular docking studies demonstrated the plausible interaction patterns of the most potent derivatives 17b and 12f in the CDK2 binding pocket and the spiro-oxindole 16a with p53-MDM2 complex, respectively. Consequently, the new chemotypes 7b, 12f, and 16a can be presented as promising antitumor hits for further studies and optimization.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
seliciclib (CYC202)
over1year
Synthesis of tricyclic and tetracyclic benzo[6,7]cycloheptane derivatives linked morpholine moiety as CDK2 inhibitors. (PubMed, Drug Dev Res)
Compounds 5 and 8 were shown to be the most effective, with half-maximal inhibitory concentration (IC ) values between 5.73 and 9.11 µM, which are on the level with doxorubicin. In addition, compounds 5 and 8 showed strong anti-CDK2 action (IC  = 0.112 and 0.18 µM, respectively) comparable to roscovitine (IC  = 0.127 µM). Moreover, the docking result demonstrated that derivatives 5 and 8 fit into the CDK2 active site in the proper orientation.
Journal
|
doxorubicin hydrochloride • seliciclib (CYC202)
over1year
Molecular Pharmacology of Multitarget Cyclin-Dependent Kinase Inhibitors in Human Colorectal Carcinoma Cells. (PubMed, Expert Opin Ther Targets)
P276-00 (also known as riviciclib), roscovitine and UCN-01 on CRC cell lines of varied genetic background were delineated. No abstract available
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression
|
7-Hydroxystaurosporine (UCN-01) • riviciclib (P27600) • seliciclib (CYC202)
over1year
Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. (PubMed, Oncogene)
We found that less-selective CDKIs, including flavopiridol, roscovitine, dinaciclib, and SNS-032, induced DR5 via p73-mediated transcriptional activation...CDKIs strongly synergized with 5-fluorouracil (5-FU), the most commonly used CRC chemotherapy agent, in vitro and in vivo to promote growth suppression and apoptosis, which required DR5 and p73. Together, these findings indicate p73-mediated DR5 induction as a potential tumor suppressive mechanism and a critical target engaged by different CDKIs in potentiating therapy-induced apoptosis in CRC cells. These findings help better understand the anticancer mechanisms of CDKIs and may help facilitate their clinical development and applications in CRC.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
5-fluorouracil • alvocidib (DSP-2033) • SNS-032 • dinaciclib (MK-7965) • seliciclib (CYC202)
almost2years
Therapeutic efficacy of cyclin-dependent kinase inhibition in combination with ionizing radiation for lung cancer. (PubMed, Int J Radiat Biol)
In vitro pretreatment with the CDK inhibitor, seliciclib, before irradiation significantly decreased the survival of A549 and H520 cells in a dose-dependent manner...An in vivo xenograft model showed that the combination of CDK inhibition and ionizing radiation delayed xenograft tumor growth, and increased the proportion of cleaved PARP-1- and cleaved caspase-3-positive cells, compared to either treatment alone. We provide preclinical tumoricidal evidence that the combination of CDK inhibition and ionizing radiation is an efficacious treatment for lung cancer.
Journal • Combination therapy • PARP Biomarker
|
CASP3 (Caspase 3) • CCNA2 (Cyclin A2)
|
PARP1 expression
|
seliciclib (CYC202)
almost2years
Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia. (PubMed, Br J Haematol)
Specifically, patients with high NRG score may benefit from treatment with anti-EGFR and CDK2 inhibitors, including erlotinib and roscovitine. The NPM1 and FLT3 mutant cell lines undergo alterations after multiple drug treatments. Our established NRG signature and scoring highlight its vital clinical significance, emphasize the inevitability of stratifying treatment for different mutation subtypes and provide new ideas to guide personalized immunotherapy strategies for AML patients.
Journal • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • CORIN (Corin, Serine Peptidase)
|
FLT3 mutation • NPM1 mutation • FLT3 mutation + NPM1 mutation
|
erlotinib • seliciclib (CYC202)
almost2years
The Expression of Cell Cycle-Related Genes in USP8-Mutated Corticotroph Neuroendocrine Pituitary Tumors and Their Possible Role in Cell Cycle-Targeting Treatment. (PubMed, Cancers (Basel))
We looked for the role of USP8 mutations or a changed p27 level in the response to palbociclib, flavopiridol and roscovitine in vitro using murine corticotroph AtT-20/D16v-F2 cells. Overexpression of mutated Usp8 in the cells did not affect the expression of p27 nor the response to the inhibitors. Downregulating or upregulating p27 expression in AtT-20/D16v-F2 cells also did not affect treatment response.
Journal
|
CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
CCND1 expression • CDKN1B expression
|
Ibrance (palbociclib) • alvocidib (DSP-2033) • seliciclib (CYC202)
2years
Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma. (PubMed, Surg Oncol)
Using available genetic atlas data, potential drug candidates for treatment of PDAC were identified based on differentially expressed genes, protein interaction analysis and connectivity mapping. These results may help focus efforts on identifying targeted agents with potential therapeutic efficacy for evaluation in prospective clinical trials of patients with PDAC.
Journal • Gene Signature
|
KRAS (KRAS proto-oncogene GTPase) • AURKA (Aurora kinase A) • SDC1 (Syndecan 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • PRSS3 (Serine Protease 3) • CCNB2 (Cyclin B2) • CDC20 (Cell Division Cycle 20) • COL3A1 (Collagen Type III Alpha 1 Chain) • CTRC (Chymotrypsin C) • ITGB1 (Integrin Subunit Beta 1) • REG1A (Lithostathine-1-alpha)
|
lapatinib • Zykadia (ceritinib) • MK-2206 • lucitanib (E 3810) • Ojjaara (momelotinib) • seliciclib (CYC202)
over2years
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. (PubMed, Leukemia)
Fadraciclib (CYC065) is a second-generation aminopurine CDK2/9 inhibitor with increased potency and selectivity toward CDK2 and CDK9 compared to seliciclib (R-roscovitine). The best combination effects were achieved when both drugs were maintained together. Altogether, this study provides a rationale for the clinical development of fadraciclib in CLL, either alone or in combination with a Bcl-2 antagonist.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CDK9 (Cyclin Dependent Kinase 9)
|
MCL1 expression
|
Venclexta (venetoclax) • fadraciclib (CYC065) • seliciclib (CYC202)
over2years
IMAGE-BASED HIGH-CONTENT DRUG SENSITIVITY SCREENING IDENTIFIES CONVENTIONAL, EMERGING, AND POTENTIAL NOVEL THERAPEUTIC TARGETS IN HIGH-RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2022)
These included pan-CDK family inhibitors alvocidib, CGP60474, and roscovitine-derived CR8. Conclusion We provide evidence that high-content drug screening in a co-culture system is an effective strategy to identify clinically-relevant novel and emerging therapeutic targets in high-risk ALL. Our analyses promote a strong rationale for exploring the targeting of CDKs as a potential pan-effective approach in high-risk adult ALL.
Clinical
|
NAMPT (Nicotinamide Phosphoribosyltransferase)
|
alvocidib (DSP-2033) • seliciclib (CYC202)
over2years
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model. (PubMed, Explor Target Antitumor Ther)
In LCC1 and LCC9 cell lines, loss of estrogen sensitivity was accompanied by loss of growth response to transforming growth factor alpha (TGFα), heregulin-beta and pertuzumab. Multiple changes occur with progression of endocrine resistance in this model with AKT activation contributing to E insensitivity and loss of ERα(Ser118) phosphorylation being associated with full resistance. Cell cycle regulation is modified in endocrine-resistant breast cancer cells, and seliciclib is effective in both endocrine-sensitive and resistant diseases.
Preclinical • Journal
|
ER (Estrogen receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • TGFA (Transforming Growth Factor Alpha) • CCNA1 (Cyclin A1)
|
MYC expression • CCND1 expression
|
Perjeta (pertuzumab) • seliciclib (CYC202)
over2years
A systems biology approach to defining tumor heterogeneity and prognostic and targetable master regulator protein signatures from bulk and single-cell RNAseq in osteosarcoma (AACR 2022)
OncoTreat analysis predicted sensitivity to camptothecin, seliciclib, galunisertib, and rigosertib in both fibroblast- and chondroblast-like subpopulations. In conclusion, using network-based systems biology approaches in OS, we identified pharmacologically accessible MR subtypes differentiating survival at the bulk tissue level, and defining three distinct tumor subpopulations at the single-cell level with unique predicted drug sensitivities.
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TOP2A (DNA topoisomerase 2-alpha) • IGF2 (Insulin-like growth factor 2) • CDK2 (Cyclin-dependent kinase 2) • FOXM1 (Forkhead Box M1) • HDAC5 (Histone Deacetylase 5) • IR (Insulin receptor) • KDM6B (Lysine Demethylase 6B) • NANOG (Nanog Homeobox) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1) • CD86 (CD86 Molecule)
|
Estybon (rigosertib) • galunisertib (LY2157299) • seliciclib (CYC202)
almost3years
Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma. (PubMed, Front Immunol)
GSs with poor survival were mainly infiltrated by mesenchymal stem cells (MSCs) and astrocyte, and were more sensitive to gefitinib and roscovitine. Among GSs, three hub genes KRT8, NGFR, and TCEA3, were screened and validated to potentially play feasible oncogenic roles in GBM. Construction of lncRNAs risk model and identification of GBM subtypes based on 17 irlncRNAs, which suggesting that irlncRNAs had the promising potential for clinical immunotherapy of GBM.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler) • NGFR (Nerve Growth Factor Receptor) • H19 (H19 Imprinted Maternally Expressed Transcript) • PLAU (Plasminogen Activator) • TCEA3 (Transcription Elongation Factor A3)
|
EGFR mutation • ATRX mutation
|
gefitinib • seliciclib (CYC202)
almost3years
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=103, Completed, Cyclacel Pharmaceuticals, Inc. | Recruiting --> Completed
Clinical • Trial completion
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
sapacitabine (CYC682) • seliciclib (CYC202)
almost3years
Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. (PubMed, Cancer Cell Int)
This study demonstrated the correlations between cellular senescence patterns and tumor immune landscape in LUAD, which enhanced our understanding of the tumor immune microenvironment and provided new insights for improving the outcome of immunotherapy for LUAD patients.
Clinical • Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • LYPD3 (LY6/PLAUR Domain Containing 3)
|
LYPD3 expression
|
MK-2206 • seliciclib (CYC202)
3years
Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma (ASH 2021)
We further found that compared to patients with low-risk score, patients with high-risk score had higher sensitivity to some drugs of targeting the immune microenvironment, including TGFβ receptor inhibitors SB525334 ( P <0.0001) and SB505124 ( P <0.0001) and immunomodulator Lenalidomide ( P =0.041), as well as NF-κB inhibitors Parthenolide ( P <0.0001) and TPCA-1 ( P <0.0001) and JAK inhibitors Ruxolitinib ( P =0.014) and TG101348 ( P =0.0053), accompanying with significantly lower IC50 values. In addition, another common chemotherapeutic drug Gemcitabine was also predicted to be more sensitive for patients with high-risk score ( P =0.047). Other targeted drugs such as Aurora kinase inhibitors VX-680 ( P <0.0001) and ZM-447439 ( P =0.014), Bcl-2 inhibitors Obatoclax Mesylate ( P =0.00036) and Navitoclax ( P <0.0001), and CDK inhibitors Roscovitine ( P =0.0012), AT-7519 ( P =0.0033), PHA-793887 ( P <0.0001) and THZ2-49 ( P =0.0053) also exhibited higher drug sensitivity for patients with high-risk score. Conclusions : PIM1 mutations play a vital role in patient risk stratification and provide novel insights into therapeutic decision making for DLBCL patients with high-risk score.
Clinical • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • PRDM1 (PR/SET Domain 1)
|
MYD88 mutation • CD79B mutation • PIM1 mutation • SPEN mutation
|
gemcitabine • lenalidomide • Jakafi (ruxolitinib) • navitoclax (ABT 263) • Inrebic (fedratinib) • PHA 793887 • AT7519 • ZM 447439 • obatoclax (GX 15-070) • seliciclib (CYC202) • tozasertib (MK-0457)